JPMorgan Chase & Co. Lowers Smith & Nephew (LON:SN) Price Target to GBX 1,290

Smith & Nephew (LON:SN) had its price target cut by equities researchers at JPMorgan Chase & Co. from GBX 1,438 to GBX 1,290 in a research report issued on Thursday, MarketBeat.com reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 15.90% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the company. Citigroup cut Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a report on Tuesday, May 5th. Shore Capital Group reissued a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a report on Tuesday, July 21st. Berenberg Bank restated a “hold” rating and issued a GBX 13 price target on shares of Smith & Nephew in a research report on Friday, May 1st. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,350 price target on shares of Smith & Nephew in a research note on Monday, June 29th. Three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Smith & Nephew currently has an average rating of “Hold” and a consensus target price of GBX 1,172.56.

Smith & Nephew Stock Up 1.4%

Shares of LON:SN opened at GBX 1,113 on Thursday. The stock’s 50-day simple moving average is GBX 1,135.36 and its 200 day simple moving average is GBX 1,192.51. The firm has a market cap of £12.20 billion, a price-to-earnings ratio of 40.07, a PEG ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.